Lurasidone (Latuda®) recommended as option for use within NHS Wales for treatment of schizophrenia in adults and adolescents aged 13 years and over

Company suggests that this second-generation atypical antipsychotic may provide an additional treatment option for patients with schizophrenia, in particular patients for whom it is clinically beneficial to avoid metabolic adverse events and weight gain.

Source:

All Wales Medicines Strategy Group